Imunon (IMNN) Shares Surge Amid Strategic Partnership Announcement

Imunon Inc. (Nasdaq: IMNN) experienced a pronounced rally of 17.82 % during the 24‑hour trading window that concluded at 02:12 PM Central Europe on Thursday, 22 October 2026. The share price, currently hovering around USD 1.19 on major exchanges, reflects a market capitalization of approximately USD 5.6 million based on a circulating supply of 5.6 million shares.

In the preceding 24 hours, roughly USD 316.9 thousand of Imunon stock was exchanged, marking a notable increase relative to the –21.19 % decline recorded since the close of the previous month. Technical indicators show a 200‑day simple moving average at USD 2.33, while the asset’s 52‑week high and low stand at USD 4.93 (10 24 2025) and USD 0.96 (10 09 2026), respectively.

Strategic Agreement with VoxelDox Therapeutics

The catalyst for the recent upside was Imunon’s announcement on 21 October 2026 that it had entered into a strategic agreement with VoxelDox Therapeutics to sell its ThermoDox® asset. Under the terms, Imunon receives an equity interest in VoxelDox, positioning the company to benefit from potential milestone payments and royalties tied to the development and commercial success of ThermoDox. These financial gains are conditional upon VoxelDox securing financing and meeting predetermined clinical and regulatory milestones.

This transaction allows Imunon to retain a long‑term economic stake in ThermoDox while reallocating resources toward the pivotal Phase 3 OVATION 3 trial of its lead immunotherapy, IMNN‑001, targeting advanced ovarian cancer. The deal exemplifies Imunon’s broader strategy of portfolio management and capital allocation within its DNA‑mediated immunotherapy program.

Market Context: Peer Performance

In the same 24‑hour period, several peer biotechnology and therapeutics stocks exhibited varied performance:

  • Ainos (AIMD) – down 2.22 %, trading at USD 0.88; market cap USD 6.7 million.
  • Enveric Biosciences (ENVB) – up 4.86 %, trading at USD 1.51; market cap USD 6.8 million.
  • Aurora Spine (ASG.V) – flat, trading at CAD 0.12; market cap CAD 9.4 million.
  • Exicure (XCUR) – up 1.1 %, trading at USD 1.01; market cap USD 6.5 million.
  • Endra Life Sciences (NDRA) – up 4.7 %, trading at USD 4.68; market cap USD 6.7 million.

These figures illustrate a mixed landscape for small‑cap biotech stocks, with Imunon standing out as a notable performer amid broader market volatility.

Company Overview

Imunon Inc. is a clinical‑stage biotechnology firm dedicated to developing innovative treatments that harness the body’s innate mechanisms to produce safe, effective, and durable responses across a spectrum of diseases. Established with an IPO on 5 March 1985, the company has grown into a global entity, listing its shares on the Nasdaq stock exchange and serving a worldwide customer base. Further information about Imunon’s research pipeline and corporate initiatives is available on its website at www.imunon.com .